Checkmate Pharmaceuticals (CMPI) News Today → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free CMPI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 30, 2022 | marketbeat.comCheckmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Short Interest UpdateCheckmate Pharmaceuticals, Inc. (NASDAQ:CMPI - Get Rating) was the target of a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 78,900 shares, an increase of 71.5% from the April 30th total of 46,000 shares. Based on an average daily trading volume, of 202,600 shares, the short-interest ratio is currently 0.4 days. Currently, 1.2% of the company's shares are short sold.May 30, 2022 | marketbeat.comTrading was temporarily halted for "CMPI" at 07:05 PM with a stated reason of "News pending."May 26, 2022 | tmcnet.comUniversity of Iowa Holden Comprehensive Cancer Center PresentsMay 26, 2022 | finance.yahoo.comUniversity of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingMay 20, 2022 | marketbeat.com Analysts Expect Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) to Post -$0.75 Earnings Per ShareBrokerages expect that Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI - Get Rating) will report earnings per share (EPS) of ($0.75) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Checkmate Pharmaceuticals' earnings. Checkmate Pharmaceuticals postMay 18, 2022 | apnews.comINVESTIGATION NOTICE: Halper Sadeh LLP Investigates TVTY, ACC, SWCH, CMPIMay 13, 2022 | seekingalpha.comCheckmate Pharmaceuticals GAAP EPS of -$0.73 beats by $0.02May 13, 2022 | finance.yahoo.comCheckmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business UpdateMay 5, 2022 | apnews.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates NLSN, CMPI, SBOWApril 29, 2022 | marketbeat.com-$0.73 EPS Expected for Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) This QuarterWall Street brokerages forecast that Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI - Get Rating) will report earnings of ($0.73) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Checkmate Pharmaceuticals' earnings. Checkmate PharmApril 29, 2022 | marketbeat.comCheckmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Major Shareholder Global Strategic Fund I. Venbio Sells 47,396 SharesCheckmate Pharmaceuticals, Inc. (NASDAQ:CMPI - Get Rating) major shareholder Global Strategic Fund I. Venbio sold 47,396 shares of the business's stock in a transaction on Wednesday, April 27th. The shares were sold at an average price of $10.38, for a total transaction of $491,970.48. Following the completion of the transaction, the insider now directly owns 2,948,463 shares of the company's stock, valued at approximately $30,605,045.94. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.April 20, 2022 | msn.comRegeneron (REGN) to Buy Checkmate Pharmaceuticals for $250MApril 20, 2022 | barrons.comShareholder Alert: Ademi LLP investigates whether Checkmate Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with RegeneronApril 19, 2022 | bizjournals.comCheckmate stock quadruples on news of Regenerate acquisitionApril 19, 2022 | finance.yahoo.comWhy Checkmate Pharmaceuticals Stock Is Rocketing Higher TodayApril 19, 2022 | stockhouse.comCMPI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Checkmate Pharmaceuticals, Inc. Is Fair to ShareholdersApril 19, 2022 | marketwatch.comCheckmate Pharmaceuticals Shares Take Flight on Regeneron Deal >CMPIApril 19, 2022 | marketbeat.comTrading was temporarily halted for "CMPI" at 07:04 AM with a stated reason of "News pending."April 8, 2022 | tmcnet.comCheckmate Pharmaceuticals Presents Clinical Trial Biomarker Data withApril 8, 2022 | finance.yahoo.comCheckmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual MeetingMarch 8, 2022 | nz.finance.yahoo.comCheckmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual MeetingMarch 8, 2022 | finance.yahoo.comCheckmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual MeetingFebruary 10, 2022 | bizjournals.comThe Petri Dish: Syndax, Checkmate get new CEOs; Biogen stays in biosimilars gameFebruary 9, 2022 | seekingalpha.comCheckmate Pharmaceuticals appoints Alan Bash as President, CEOFebruary 9, 2022 | finance.yahoo.comCheckmate Pharmaceuticals Appoints Alan Bash as President and CEOJanuary 31, 2022 | nasdaq.comCheckmate Pharmaceuticals, Inc. Common Stock (CMPI)January 31, 2022 | finance.yahoo.comCheckmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of DirectorsJanuary 7, 2022 | nasdaq.comHere's Why We're A Bit Worried About Checkmate Pharmaceuticals' (NASDAQ:CMPI) Cash Burn SituationJanuary 3, 2022 | finance.yahoo.comCheckmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual ConferenceDecember 20, 2021 | finance.yahoo.comCheckmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Multi-Indication Trial Using VidutolimodNovember 15, 2021 | finance.yahoo.comCheckmate Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare ConferenceNovember 12, 2021 | finance.yahoo.comCheckmate Pharmaceuticals Presents Final Clinical Data for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual MeetingNovember 12, 2021 | finance.yahoo.comCheckmate Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business UpdateNovember 11, 2021 | finance.yahoo.comCheckmate Pharmaceuticals to Present at the Jefferies London Healthcare ConferenceNovember 1, 2021 | finance.yahoo.comCheckmate Pharmaceuticals Announces Final Data Presentation for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual MeetingOctober 27, 2021 | finance.yahoo.comCheckmate Pharmaceuticals Announces CEO TransitionOctober 20, 2021 | finance.yahoo.comCheckmate Pharmaceuticals Announces Webcast on Innate Immune Modulators and Vidutolimod (CMP-001)October 13, 2021 | finance.yahoo.comWe're Keeping An Eye On Checkmate Pharmaceuticals' (NASDAQ:CMPI) Cash Burn RateOctober 9, 2021 | nasdaq.comOne Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) insider upped their stake by 2.5% in the previous yearOctober 6, 2021 | markets.businessinsider.comWhy BofA Turned Bullish On Checkmate Pharmaceuticals, But Slashed Price TargetSeptember 14, 2021 | finance.yahoo.comCheckmate Pharmaceuticals to Present at the Cantor Virtual Global Healthcare ConferenceSeptember 7, 2021 | finance.yahoo.comCheckmate Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceAugust 21, 2021 | nasdaq.comPeek Under The Hood: VTI Has 11% UpsideAugust 12, 2021 | barrons.comCheckmate Pharmaceuticals Inc.August 12, 2021 | finance.yahoo.comCheckmate Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business UpdateAugust 2, 2021 | finance.yahoo.comCheckmate Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference Get Checkmate Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPI and its competitors with MarketBeat's FREE daily newsletter. Email Address Does this make you sick? (Ad)The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments. Get your Free Wealth Protection Kit CMPI Media Mentions By Week CMPI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMPI News Sentiment▼0.000.42▲Average Medical News Sentiment CMPI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMPI Articles This Week▼00▲CMPI Articles Average Week Get Checkmate Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Agenus News Today Coherus BioSciences News Today Zura Bio News Today Compass Therapeutics News Today Acumen Pharmaceuticals News Today Metagenomi News Today Innate Pharma News Today Opthea News Today Monte Rosa Therapeutics News Today INmune Bio News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMPI) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDoes this make you sick?Allegiance GoldUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward PressGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkmate Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
